Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Christopher G. Nasveschuk"'
Autor:
Qi Hao, Manoj K. Rathinaswamy, Kelly L. Klinge, Matthew Bratkowski, Amirhossein Mafi, Christina K. Baumgartner, Keith M. Hamel, Gesine K. Veits, Rinku Jain, Claudio Catalano, Mark Fitzgerald, Alexander W. Hird, Eunice Park, Harit U. Vora, James A. Henderson, Kenton Longenecker, Charles W. Hutchins, Wei Qiu, Giovanna Scapin, Qi Sun, Vincent S. Stoll, Chaohong Sun, Ping Li, Dan Eaton, David Stokoe, Stewart L. Fisher, Christopher G. Nasveschuk, Marcia Paddock, Michael E. Kort
Publikováno v:
Communications Chemistry, Vol 7, Iss 1, Pp 1-16 (2024)
Abstract PTPN2 (protein tyrosine phosphatase non-receptor type 2, or TC-PTP) and PTPN1 are attractive immuno-oncology targets, with the deletion of Ptpn1 and Ptpn2 improving response to immunotherapy in disease models. Targeted protein degradation ha
Externí odkaz:
https://doaj.org/article/1f2680b79836478cba894b08e1a585a6
Autor:
Anthony D. Piscopio, Xuedong Liu, S. Gail Eckhardt, William P. Schiemann, Michael K. Wendt, James D. Winkler, John A. DeMattei, Sarah J. Hartman, Brian Gittleman, John J. Tentler, Timothy P. Newton, Betelehem W. Yacob, Jessica Pafford, Stacey M. Bagby, Andrew J. Phillips, Gan Zhang, Christopher G. Nasveschuk, Dana Ungermannova, Todd M. Pitts, Jennifer R. Diamond
Supplementary Data from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b66cc0ba3e4bb3154d809f1ce9e18868
https://doi.org/10.1158/1535-7163.22522086
https://doi.org/10.1158/1535-7163.22522086
Autor:
Anthony D. Piscopio, Xuedong Liu, S. Gail Eckhardt, William P. Schiemann, Michael K. Wendt, James D. Winkler, John A. DeMattei, Sarah J. Hartman, Brian Gittleman, John J. Tentler, Timothy P. Newton, Betelehem W. Yacob, Jessica Pafford, Stacey M. Bagby, Andrew J. Phillips, Gan Zhang, Christopher G. Nasveschuk, Dana Ungermannova, Todd M. Pitts, Jennifer R. Diamond
Histone deacetylases (HDACs) play critical roles in epigenomic regulation, and histone acetylation is dysregulated in many human cancers. Although HDAC inhibitors are active in T-cell lymphomas, poor isoform selectivity, narrow therapeutic indices, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ca10d3d7a768f89abeba39b0600ff66
https://doi.org/10.1158/1535-7163.c.6543273
https://doi.org/10.1158/1535-7163.c.6543273
Autor:
Anthony D. Piscopio, Xuedong Liu, S. Gail Eckhardt, William P. Schiemann, Michael K. Wendt, James D. Winkler, John A. DeMattei, Sarah J. Hartman, Brian Gittleman, John J. Tentler, Timothy P. Newton, Betelehem W. Yacob, Jessica Pafford, Stacey M. Bagby, Andrew J. Phillips, Gan Zhang, Christopher G. Nasveschuk, Dana Ungermannova, Todd M. Pitts, Jennifer R. Diamond
Supplementary Figure from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21396584792a719c719476ad7fe8d703
https://doi.org/10.1158/1535-7163.22522083
https://doi.org/10.1158/1535-7163.22522083
Autor:
Jennifer R. Diamond, Todd M. Pitts, Dana Ungermannova, Christopher G. Nasveschuk, Gan Zhang, Andrew J. Phillips, Stacey M. Bagby, Jessica Pafford, Betelehem W. Yacob, Timothy P. Newton, John J. Tentler, Brian Gittleman, Sarah J. Hartman, John A. DeMattei, James D. Winkler, Michael K. Wendt, William P. Schiemann, S. Gail Eckhardt, Xuedong Liu, Anthony D. Piscopio
Publikováno v:
Mol Cancer Ther
Histone deacetylases (HDACs) play critical roles in epigenomic regulation, and histone acetylation is dysregulated in many human cancers. Although HDAC inhibitors are active in T-cell lymphomas, poor isoform selectivity, narrow therapeutic indices, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e7f204038b194d4d2b23b9b7512f1bf
https://doi.org/10.1158/1535-7163.mct-21-0455
https://doi.org/10.1158/1535-7163.mct-21-0455
Autor:
Jodi Shaulsky, Andrew C. Good, Roman V. Agafonov, Tobie D. Lee, Christopher G. Nasveschuk, Andrew J. K. Phillips, Joe Sahil Patel, Ryan E. Michael, Hongwei Huang, Scott J. Eron, Mark E. Fitzgerald, Stewart L. Fisher, Ashley A. Hart
Publikováno v:
'ACS Chemical Biology ', vol: 16, pages: 2228-2243 (2021)
The field of targeted protein degradation (TPD) has grown exponentially over the past decade with the goal of developing therapies that mark proteins for destruction leveraging the ubiquitin-proteasome system. One common approach to achieve TPD is to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1cbcbb46e22a554e95dd60b690230ec
https://doi.org/10.1021/acschembio.1c00376
https://doi.org/10.1021/acschembio.1c00376
Autor:
Alexander M. Taylor, Chris Bailey, Lisa D. Belmont, Robert Campbell, Nico Cantone, Alexandre Côté, Terry D. Crawford, Richard Cummings, Kevin DeMent, Martin Duplessis, Megan Flynn, Andrew C. Good, Hon-Ren Huang, Shivangi Joshi, Yves Leblanc, Jeremy Murray, Christopher G. Nasveschuk, Adrianne Neiss, Florence Poy, F. Anthony Romero, Peter Sandy, Yong Tang, Vickie Tsui, Laura Zawadzke, Robert J. Sims, James E. Audia, Steven F. Bellon, Steven R. Magnuson, Brian K. Albrecht, Andrea G. Cochran
Publikováno v:
Journal of medicinal chemistry. 65(16)
Bromodomains are acetyllysine recognition domains present in a variety of human proteins. Bromodomains also bind small molecules that compete with acetyllysine, and therefore bromodomains have been targets for drug discovery efforts. Highly potent an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e88d18fd974b18b10231a436e2238a9
https://pubmed.ncbi.nlm.nih.gov/35930799
https://pubmed.ncbi.nlm.nih.gov/35930799
Autor:
David A. Proia, Zhigang Tu, Linda Lee, Ryan E. Michael, Christopher G. Nasveschuk, Danlin Sun, Mark E. Fitzgerald, Alexander Y. Deneka, Stewart L. Fisher, Anna C. Lilly, Anna S. Nikonova, Peishan Zhang, Andrew J. Phillips, Erica A. Golemis
Publikováno v:
Mol Cancer Ther
Targeted, catalytic degradation of oncoproteins using heterobifunctional small molecules is an attractive modality, particularly for hematologic malignancies, which are often initiated by aberrant transcription factors and are challenging to drug wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64abfe3d18e64103ac9017aeed1e325c
https://doi.org/10.1158/1535-7163.mct-20-0831
https://doi.org/10.1158/1535-7163.mct-20-0831
Autor:
Stewart L. Fisher, Marta Isasa, Stephen Archer, Heng Li, Mark E. Fitzgerald, Lydia Emerson, Christopher G. Nasveschuk, Linda Lee, Roman V. Agafonov, Richard W. Deibler, Jeffrey R Simard, Ryan E. Michael, Ellen F. Vieux, Brendon Ladd, David A. Proia, Gunther Kern, Eunice S. Park, Andrew J. K. Phillips, David Cocozziello
Publikováno v:
SLAS Discovery. 26:547-559
Recent advances in targeted protein degradation have enabled chemical hijacking of the ubiquitin-proteasome system to treat disease. The catalytic rate of cereblon (CRBN)-dependent bifunctional degradation activating compounds (BiDAC), which recruit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b95d7f93321f5de660b39ea7553ea25
https://doi.org/10.1177/24725552211000673
https://doi.org/10.1177/24725552211000673
Autor:
Yanke Liang, Mathew E. Sowa, Katrina L. Jackson, Jeffrey R. Simard, Bridget Kreger, Ping Li, Laura Poling, Joelle Baddour, Andrew Good, Hongwei Huang, Scott Eron, Christopher G. Nasveschuk, Robert Yu, Mark Fitzgerald, Victoria Garza, Morgan W. O’Shea, Gesine Veits, Jeremy Y. Yap, Moses Moustakim, Ashley Hart, Roman V. Agafonov, Grace Sarkissian, Joe S. Patel, Richard Deibler, Kyle S. Cole, David Cocozziello, Fazlur Rahman, Andrew J. Phillips, Elizabeth Norton, Adam S. Crystal, Roy M. Pollock, Stewart L. Fisher
Publikováno v:
Cancer Research. 83:3425-3425
The BRAF kinase plays a critical role in the MAPK signaling pathway and is mutated in ~8% of all human cancers including melanoma (~60%), thyroid (~60%), and lung adenocarcinoma (~10%). The most common mutation in BRAF is V600E (Class I), which is fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4eb2b150c4dde824e5ce0d7e8249985a
https://doi.org/10.1158/1538-7445.am2023-3425
https://doi.org/10.1158/1538-7445.am2023-3425